Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater!

The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater! EDITORIAL The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater! Piero Pollesello, PhD* and Zoltán Papp, MD, PhD† e listened with interest to a lively debate during the recent European Society of WCardiology (ESC) annual congress in Barcelona. The question under consideration was the role of inotropes in heart failure at large: “.are they dead and buried?” The answer that emerged from an amicable, but keenly contested exchange between Professor Milton Packer and Professor Gerhard Pölzl was that “.it depends on which inotrope and on which subtype of heart failure.” We summarize in this Comment some of the points that attracted our attention. “Inotrope” is nowadays a much more sophisticated and capacious term than hitherto with a recent classification proposing a subdivision in the 3 categories of calcitropes, myotropes, and mitotropes : (1) Calcitropes are drugs increasing contractility by an ele- vation of intracellular calcium, such as the beta-agonist dobutamine, the phosphodiesterase inhibitor milrinone, or the sodium pump inhibitor digoxin; (2) Myotropes are drugs increas- ing contractility by a direct interaction with the contractile proteins, such as the troponin C activator levosimendan or the myosin activator omecamtiv mecarbil; (3) Mitotropes are drugs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cardiovascular Pharmacology Wolters Kluwer Health

The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater!

Loading next page...
 
/lp/wolters-kluwer-health/the-future-for-inotropes-in-heart-failure-do-not-throw-the-baby-out-fzYs0TL0gF

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0160-2446
eISSN
1533-4023
DOI
10.1097/fjc.0000000000001377
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater! Piero Pollesello, PhD* and Zoltán Papp, MD, PhD† e listened with interest to a lively debate during the recent European Society of WCardiology (ESC) annual congress in Barcelona. The question under consideration was the role of inotropes in heart failure at large: “.are they dead and buried?” The answer that emerged from an amicable, but keenly contested exchange between Professor Milton Packer and Professor Gerhard Pölzl was that “.it depends on which inotrope and on which subtype of heart failure.” We summarize in this Comment some of the points that attracted our attention. “Inotrope” is nowadays a much more sophisticated and capacious term than hitherto with a recent classification proposing a subdivision in the 3 categories of calcitropes, myotropes, and mitotropes : (1) Calcitropes are drugs increasing contractility by an ele- vation of intracellular calcium, such as the beta-agonist dobutamine, the phosphodiesterase inhibitor milrinone, or the sodium pump inhibitor digoxin; (2) Myotropes are drugs increas- ing contractility by a direct interaction with the contractile proteins, such as the troponin C activator levosimendan or the myosin activator omecamtiv mecarbil; (3) Mitotropes are drugs

Journal

Journal of Cardiovascular PharmacologyWolters Kluwer Health

Published: Jan 1, 2023

References